A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.

Brief description of study

The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that can be taken safely (maximum tolerated dose, abbreviated as MTD). • Evidence of anti-cancer activity responses in patients receiving CX-2029, including how long patients live. • Whether or not your body develops antibodies to CX-2029 that may affect its ability to attach to your tumor (immunogenicity). • The amount of CX-2029 in your blood and how long CX-2029 stays in your body. • Whether certain markers of iron metabolism affect the safety or activity of CX-2029 in your body • Whether CX-2029 binds to its target (CD71) in your body • Levels of certain markers which might help characterize the cancer within your tumor, blood or urine (for some patients). • How much CX-2029 is actually active within the tumor (for some patients).

Clinical Study Identifier: s18-00093
ClinicalTrials.gov Identifier: NCT03543813

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.